These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 32892447)

  • 1. Early cytomegalovirus DNAemia and antiviral dose adjustment in high vs intermediate risk kidney transplant recipients.
    Schaenman J; Phonphok K; Spanuchart I; Duong T; Sievers TM; Lum E; Reed EF; Bunnapradist S
    Transpl Infect Dis; 2021 Feb; 23(1):e13457. PubMed ID: 32892447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-Dose Valganciclovir Prophylaxis Is Safe and Cost-Saving in CMV-Seropositive Kidney Transplant Recipients.
    Shi Y; Lerner AH; Rogers R; Vieira K; Merhi B; Mecadon K; Osband AJ; Bayliss G; Gohh R; Morrissey P; Farmakiotis D
    Prog Transplant; 2021 Dec; 31(4):368-376. PubMed ID: 34839729
    [No Abstract]   [Full Text] [Related]  

  • 3. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight-based dosed valganciclovir prophylaxis.
    Liverman R; Serluco A; Nance G; George R; Rodriguez DS; Deshpande S; Mao C; Garro R; Yildirim I
    Pediatr Transplant; 2023 Jun; 27(4):e14493. PubMed ID: 36945819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
    Limaye AP; Budde K; Humar A; Vincenti F; Kuypers DRJ; Carroll RP; Stauffer N; Murata Y; Strizki JM; Teal VL; Gilbert CL; Haber BA
    JAMA; 2023 Jul; 330(1):33-42. PubMed ID: 37279999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A split strategy to prevent cytomegalovirus after kidney transplantation using prophylaxis in serological high-risk patients and a pre-emptive strategy in intermediate-risk patients: Combining the best of two options?
    Hellemans R; Wijtvliet V; Bergs K; Philipse E; Vleut R; Massart A; Couttenye MM; Matheeussen V; Abramowicz D
    Transpl Infect Dis; 2021 Apr; 23(2):e13467. PubMed ID: 32935909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients.
    Reischig T; Vlas T; Kacer M; Pivovarcikova K; Lysak D; Nemcova J; Drenko P; Machova J; Bouda M; Sedivcova M; Kormunda S
    J Am Soc Nephrol; 2023 May; 34(5):920-934. PubMed ID: 36749127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
    BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis.
    Paulsen G; Cumagun P; Mixon E; Fowler K; Feig D; Shimamura M
    Pediatr Transplant; 2019 May; 23(3):e13382. PubMed ID: 30786115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
    Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
    JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.
    Perrottet N; Manuel O; Lamoth F; Venetz JP; Sahli R; Decosterd LA; Buclin T; Pascual M; Meylan P
    BMC Infect Dis; 2010 Jan; 10():2. PubMed ID: 20053269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
    Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GCV/VCVG prophylaxis against CMV DNAemia in pediatric renal transplant patients: A systematic review and meta-analysis.
    Chatani B; Glaberson W; Nemeth Z; Tamariz L; Gonzalez IA
    Pediatr Transplant; 2019 Sep; 23(6):e13514. PubMed ID: 31210393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
    Myhre HA; Haug Dorenberg D; Kristiansen KI; Rollag H; Leivestad T; Asberg A; Hartmann A
    Transplantation; 2011 Jul; 92(2):217-23. PubMed ID: 21685829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
    Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
    Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
    Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
    Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.
    Lautenschlager I; Loginov R; Mäkisalo H; Höckerstedt K
    J Clin Virol; 2015 Oct; 71():73-5. PubMed ID: 26318605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The burden of cytomegalovirus infection remains high in high-risk kidney transplant recipients despite six-month valganciclovir prophylaxis.
    Räihä J; Ortiz F; Mannonen L; Loginov R; Lempinen M; Lautenschlager I; Helanterä I
    Transpl Infect Dis; 2021 Aug; 23(4):e13577. PubMed ID: 33527660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors of spontaneous CMV DNAemia clearance in kidney transplantation.
    Noble J; Gatault P; Sautenet B; Gaudy-Graffin C; Beby-Defaux A; Thierry A; Essig M; Halimi JM; Munteanu E; Alain S; Buchler M
    J Clin Virol; 2018; 99-100():38-43. PubMed ID: 29306112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
    Chiereghin A; Potena L; Borgese L; Gibertoni D; Squarzoni D; Turello G; Petrisli E; Piccirilli G; Gabrielli L; Grigioni F; Lazzarotto T
    J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29305542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can preemptive cytomegalovirus monitoring be as effective as universal prophylaxis when implemented as the standard of care in patients at moderate risk?
    McGillicuddy JW; Weimert NA; Taber DJ; Turner A; Mitchell LA; Wray DW; Egidi MF; Kuppachi S; Hughes MG; Baliga PK; Chavin KD
    Transplantation; 2010 May; 89(10):1218-23. PubMed ID: 20410854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.